Balancing efficacy and safety through VCN analysis
Vector copy number is all about balancing efficacy against safety. More copies will increase efficacy but also the potential risk of oncogenesis. We quantify the vector copy number for dosing, potency, and safety assessments.
What is Vector Copy Number (VCN) and why it matters
Vector copy number (VCN) represents the quantity of transgene DNA in genetically modified cells or viral gene therapy products before administration. The FDA raises concerns about potential oncogenicity due to the risk of pathological insertions associated with vector-mediated genetic modification. To address these safety concerns, measuring transgene copies within cell therapy products and quantifying the VCN is required. More integrated transgene copies are believed to enhance product potency as well as increase the oncogenic potential by random vector integration into the host genome. Therefore, the objective is to balance an effective VCN with minimizing associated risks.
FDA approval for clinical use mandates limiting CAR-T VCN to fewer than five vector copies per transduced cell, reducing the number of vector insertion sites in the host genome.
VCN quantification for in vivo gene therapies
For in vivo administered viral gene therapy products, accurate quantification of the viral genome titer is crucial for dosing and potency analysis. To assess VCN persistence in cell therapies and in vivo administered viral gene therapies, various techniques such as qPCR, dPCR, or NGS are employed to amplify integrated viral vector sequences in genomic DNA obtained from biospecimens. These analyses contribute to gene therapy products’ overall safety and efficacy assessment.
Fast, Fit-for-Purpose VCN analysis to accelerate drug development
Our vector copy number (VCN) analysis is tailored to support nonclinical and clinical stages of drug development, helping you generate the data needed for regulatory submissions and decision-making. With rapid turnaround times and assays optimized for sensitivity, accuracy, and relevance, we quantify VCN in gene-modified cells and biospecimens to assess dosing, persistence, potency, and safety. Designed for flexibility, our fit-for-purpose approach ensures you get regulatory-ready data.
Your partner in end-to-end Vector Copy Number analysis
We offer short lead times and fast analyses, allowing you to quickly generate critical vector copy number (VCN) data to inform dosing, potency, and safety decisions throughout drug development. Our services also support the optimization of purification processes, increase confidence in your products before GMP analysis, assist with deviation control, and ensure trust in GMP results and safe product delivery.
Our well-equipped molecular analysis laboratory features automated platforms, a Laboratory Information Management System (LIMS), and high-throughput instruments for qPCR, dPCR, and Next-Generation Sequencing (NGS). Additionally, our facility includes a Biosafety Level 2 (BSL-2) laboratory that allows us to offer end-to-end solutions, from sample extraction to data transfer.
Supporting Vector Copy Number Analysis for Cell & Gene Therapy Development
Accurate vector copy number (VCN) quantification is critical for characterizing gene-modified products like CAR-T and other cell and gene therapies. At TATAA Biocenter, we specialize in fit-for-purpose method development and validation using qPCR and digital PCR platforms, ensuring robust, regulatory-ready, reproducible data across a variety of biological matrices.
With deep expertise in cell and gene therapy bioanalysis, we tailor each assay to match your project’s specific vector design, cell type, and regulatory phase. Whether you’re in early research or preparing for IND-enabling studies, we provide regulatory-ready support to help you meet evolving expectations with confidence.